A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy

Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies

(2020) Theodore L. Roth et al.   CELL

T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy

(2019) Tori N. Yamamoto et al.   JOURNAL OF CLINICAL INVESTIGATION

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

(2019) Aude G. Chapuis et al.   NATURE MEDICINE

Engineered adoptive T-cell therapy prolongs survival in a preclinical model of advanced stage ovarian cancer

(2019) Kristin G. Anderson et al.   Cancer Immunology Research

T Cell Dysfunction in Cancer

(2018) Daniela S. Thommen et al.   CANCER CELL

4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses

(2018) Ashley V. Menk et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

CAR-T cells: the long and winding road to solid tumors

(2018) Maria Michela D’Aloia et al.   Cell Death & Disease

Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation

(2018) Alvaro Teijeira et al.   Cancer Immunology Research

Apoptosis of tumor-infiltrating T lymphocytes: a new immune checkpoint mechanism

(2018) Jingjing Zhu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent

(2017) Diogo Gomes-Silva et al.   Cell Reports

A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors

(2016) Xiaojun Liu et al.   CANCER RESEARCH

4-1BB signaling activates glucose and fatty acid metabolism to enhance CD8+ T cell proliferation

(2016) Beom K Choi et al.   Cellular & Molecular Immunology

Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy

(2016) Alfonso R. Sanchez-Paulete et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells

(2016) Omkar U. Kawalekar et al.   IMMUNITY

Protein Translation Activity: A New Measure of Host Immune Cell Activation

(2016) Mina O. Seedhom et al.   JOURNAL OF IMMUNOLOGY

Filling the Tank: Keeping Antitumor T Cells Metabolically Fit for the Long Haul

(2016) G. M. Delgoffe   Cancer Immunology Research

Role of IL-2 in cancer immunotherapy

(2016) Tao Jiang et al.   OncoImmunology

T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma

(2015) Ingunn M. Stromnes et al.   CANCER CELL

Erratum: The role of CD95 and CD95 ligand in cancer

(2015) M E Peter et al.   CELL DEATH AND DIFFERENTIATION

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors

(2015) Adrienne H Long et al.   NATURE MEDICINE

Impact of a New Fusion Receptor on PD-1–Mediated Immunosuppression in Adoptive T Cell Therapy

(2015) Sebastian Kobold et al.   JNCI-Journal of the National Cancer Institute

Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD

(2015) A. Kunkele et al.   Cancer Immunology Research

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

(2015) Todd Bartkowiak et al.   Frontiers in Oncology

Inactivation of the Transcription Factor GLI1 Accelerates Pancreatic Cancer Progression

(2014) Lisa D. Mills et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors

(2014) Gregory T Motz et al.   NATURE MEDICINE

Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII+FasL+ Killer Exosomes

(2014) Matthew W. Klinker et al.   Frontiers in Immunology

Systemic 4-1BB activation induces a novel T cell phenotype driven by high expression of Eomesodermin

(2013) Michael A. Curran et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity

(2013) C. Ankri et al.   JOURNAL OF IMMUNOLOGY

4-1BB Signaling Activates the T Cell Factor 1 Effector/β-Catenin Pathway with Delayed Kinetics via ERK Signaling and Delayed PI3K/AKT Activation to Promote the Proliferation of CD8+ T Cells

(2013) Do Y. Lee et al.   PLoS One

Targeting the Fas/FasL signaling pathway in cancer therapy

(2012) María Villa-Morales et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor

(2012) Megan E. Prosser et al.   MOLECULAR IMMUNOLOGY

Mitochondrial Respiratory Capacity Is a Critical Regulator of CD8+ T Cell Memory Development

(2011) Gerritje J.W. van der Windt et al.   IMMUNITY

Abrogating Cbl-b in effector CD8+ T cells improves the efficacy of adoptive therapy of leukemia in mice

(2010) Ingunn M. Stromnes et al.   JOURNAL OF CLINICAL INVESTIGATION

Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand

(2009) A. Wyzgol et al.   JOURNAL OF IMMUNOLOGY

Relationship between CD107a expression and cytotoxic activity

(2008) Esin Aktas et al.   CELLULAR IMMUNOLOGY